聯邦製藥(03933.HK)附屬兩款治療糖尿病藥獲批
聯邦製藥(03933.HK)公佈,於週一(12日),全資附屬珠海聯邦製藥所申報的門冬胰島素注射液及門冬胰島素30注射液,已通過國家藥監局藥品註冊審批。
門冬胰島素爲速效胰島素類似物,適用於糖尿病的治療,可用於皮下注射和胰島素泵輸注給藥。與可溶性人胰島素相比,門冬胰島素起效迅速,安全性高,可明顯改善餐後血糖水平。門冬胰島素30爲預混胰島素類似物,由30%可溶性門冬胰島素和 70%精蛋白門冬胰島素組成,該藥起效迅速,可更好控制餐後血糖水平,減少低血糖發生風險,在提高患者依從性方面優勢明顯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.